Skip to content
← Full study record

NCT00985907 · MORE INFO

Limitations, agreements, and source contact

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma · Source last updated 2020-06-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Enrollment was terminated early due to low accrual in Phase 1. No participants were enrolled in Phase 2. Participant flow, baseline, and adverse event data was electronically transferred from a legacy clinical trials database by phase group only.
point Of Contact
email
Tom.Martin@ucsf.edu
organization
University of California, San Francisco
phone
(415) 353-9365
title
Dr. Thomas Martin, MD
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Enrollment was terminated early due to low accrual in Phase 1. No participants were enrolled in Phase 2. Participant flow, baseline, and adverse event data was electronically transferred from a legacy clinical trials database by phase group only.
point Of Contact
email
Tom.Martin@ucsf.edu
organization
University of California, San Francisco
phone
(415) 353-9365
title
Dr. Thomas Martin, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice